Atlas Trials

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Clinical trial NCT03256136 · COMPLETED

Trial details

NCT number
NCT03256136
Sponsor
Massachusetts General Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer
Start date
2017-11-22
Primary completion
2019-08-19
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.